secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rallybio Corp (RLYB)
CIK:        0001739410
Form:       8-K
Filed at:   2021-11-10T23:59:59+00:00
Accession:  0000950170-21-003919
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rallybio Q3 net loss $10.2M ($0.37/share); cash $187M; pipeline on track
------------------------------------------------------------------------

- Net loss $10.2M vs $7.2M in Q3 2020; R&D $5.0M flat; G&A $5.0M up from $1.6M.
- Cash and equivalents $187.0M, including $83M net from August 2021 IPO.
- Initiated FNAIT natural history study to support RLYB212 registration trial design.
- On-track to report additional Phase 1/2 RLYB211 data in Q4 2021.
- Phase 1 studies for RLYB212 and RLYB116 expected to start in Q1 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739410/000095017021003919/0000950170-21-003919-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739410/000095017021003919/rlyb-20211110.htm
  HTML page:      https://secwatch.observer/filing/0000950170-21-003919

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer